Evommune (EVMN) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

—

Revenue (quarter)

—

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

—

Gross margin

—

Net income (trailing twelve months)

—

Net income (quarter)

−$32.2M

Net income growth (year over year)

−137.71%

Net margin

—

Return on equity

−178.03%

EPS (trailing twelve months)

$5.53

Book value per share

$7.65

P/E (trailing twelve months)

—

Price to book

0.77

Debt to assets

8.07%

Payout ratio

—

Dividend yield

—

Company profile

Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.

• How do I buy stock in Evommune (EVMN)?

  EVMN trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.